Empagliflozin Treatment in Kidney Transplant Recipients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 264 participants.
Also called NCT06013865
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 264 participants
- Registry
-
NCT06013865
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06013865. Allocation not applicable; no masking; primary purpose treatment. Start 2024-04-05 (actual); primary completion 2030-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin Treatment in Kidney Transplant Recipients
- Acronym
- SEKTR
- Condition
- Kidney Transplant
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Empagliflozin
- Lead sponsor
- VA Office of Research and Development
- Collaborator
- Iowa City VA Health Care System
- Collaborator
- VA Pittsburgh Healthcare System
- Collaborator
- VA Tennessee Valley Health Care System
- Collaborator
- VA Hines Health Care
Record details
- Record id
cardio:ct-nct06013865- Content hash
ab26ae8ac52d4933ab143d9723804ce6c307f6e4ab10dac42f56c55e83eced7d